

Multiple Sclerosis Committee meeting 13

Date: 28/02/2022

Location: Video-conference

Minutes: Final

Committee members present:	
Paul Cooper (Chair)	(Present for notes 1 – 4)
Olga Ciccarelli (Topic adviser)	
Lloyd Bradley	
Daisy Cam	
Aleks De Gromoboy	
Sue Edwards	
Jenny Freeman	
Hayley Hall	
Sushmita Mohapatra	
Yvonne Pettigrew	
Aoife Shields	
Jason Wigham	

In attendance:		
Catrina Charlton	Guideline Commissioning Manager, NICE	
Catharine Baden-Daintree	Senior Medical Editor, NICE	
Amy Crisp	Senior Project Manager, NGC	
Saoussen Ftouh	Senior Research Fellow, NGC	
Sophia Kemmis Betty	Senior Health Economist, NGC	
Claire Sloan	Health Economist, NGC	
Sharon Swain	Guideline Lead, NGC	

4.0.03 DOC Cmte minutes

Apologies:	
Sonia Devereux	General Practitioner, Fife
Nicole Downes	Research Fellow, NGC
Robert Brenner	Consultant Neurologist, Royal Free Hospital
Heather Angus-Leppan	Consultant Neurologist, Royal Free Hospital, London
Glenda Gapitano (co-optee)	Safeguarding and Risk Manager, Adult Social Care, Leeds
Emma Nicholas (co-optee)	Clinical Nurse Specialist in Palliative care, Royal Trinity Hospice, London

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the thirteenth meeting on Multiple Sclerosis.

Apologies were received for this meeting. These are noted above.

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matters under discussion were:

- All recommendations

The Chair asked everyone to verbally declare any interests.

Name	Job title, organisation	Declarations of Interest	Type of interest	Decision taken
Hayley Hall	Lay member	Service user advisor, Health and Care Professionals Council	Direct - financial	No action other than the process of open declaration.
Hayley Hall	Lay member	Lay member of the Royal College of Veterinary Surgeons Ethics Review Panel (ERP)	Direct – financial	No action other than the process of open declaration
Aoife Shields	Principle Pharmacist- Multiple	Novartis Internal Cycle Meeting I had a meeting with	Direct – financial	Partial exclusion, withdraw from

4.0.03 DOC Cmte minutes

	Sclerosis, National Hospital for Neurology and Neurosurgery	members of the Novartis team for example medical scientific liaison officers (MSL) and key account holders (KAH). They were interested in discussing the challenges of setting up an ofatumumab treatment pathway. Queen Square MS service have set up the service quickly and before many other UK MS services. The Novartis team requested a meeting with me to discuss how our service was set up and if there were any particular problems areas that they can have knowledge of so that they can provide support to other services. The meeting was a 2 hour question and answer. I was paid for my time.		recommendation making discussions on intrathecal baclofen.
<p>It was agreed that AS would withdraw from recommendation making discussions on intrathecal baclofen.</p>				
3. Presentations, questions and discussion				
<p>SF and SKB presented the stakeholder comments to the committee. The committee reviewed the comments and made edits to the guideline based on this.</p>				
4. Any other business				
<p>The Chair thanked all committee members for their involvement in this guideline.</p>				